Sutro Biopharma Newsroom

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Latest 24% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures

Yahoo FinanceDec 19 14:31 ET

Sutro Biopharma Is Maintained at Equal-Weight by Wells Fargo

Dow JonesDec 11 15:00 ET · Ratings

Sutro Biopharma Price Target Cut to $4.00/Share From $5.00 by Wells Fargo

Dow JonesDec 11 15:00 ET · Ratings

Express News | JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target

BenzingaDec 11 12:32 ET

Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating

Moomoo NewsDec 11 08:33 ET · Ratings

TD Cowen Maintains Sutro Biopharma(STRO.US) With Buy Rating

Moomoo NewsDec 11 08:33 ET · Ratings

A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $4 to $17

Moomoo NewsDec 11 08:00 ET · Ratings

TD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TipRanksDec 11 07:25 ET · Ratings

Cautious Hold Rating on Sutro Biopharma Amid Mixed Luvelta Outlook and Delayed Timeline

TipRanksDec 11 05:07 ET · Ratings

Strong Buy Rating for Sutro Biopharma Amid Promising Trial Results and Strategic Financial Position

TipRanksDec 11 00:25 ET · Ratings

Sutro Biopharma Announces Selected Doses From REFRalphaME-O1

TipRanksDec 10 08:15 ET

Sutro Biopharma Announces Selected Dose For Luvelta And Topline Results From Dose-Optimization Portion Of REFRαME-O1 Trial In Platinum Resistant Ovarian Cancer; 32% Objective Response Rate In Evaluable Patients At The 5.2 Mg/kg Starting Dose, The...

BenzingaDec 10 08:04 ET

Express News | Sutro Biopharma Inc - Luvelta Positioned for Accelerated Approval Application in Mid-2027

ReutersDec 10 08:01 ET

Express News | Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results From Dose-Optimization Portion of RefrΑMe-O1 Trial in Platinum Resistant Ovarian Cancer

ReutersDec 10 08:00 ET

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results From Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

Sutro BiopharmaDec 10 00:00 ET

Investors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) Tunnel And Push Stock Down 27%

Simply Wall StNov 25 06:04 ET

Time To Worry? Analysts Just Downgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Outlook

Simply Wall StNov 20 05:15 ET

H.C. Wainwright Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsNov 19 03:36 ET · Ratings

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Yahoo FinanceNov 18 12:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target

BenzingaNov 18 07:22 ET